Investors

  • 2021-04-15
    VOLUNTARY ANNOUNCEMENT APPOINTMENT OF CHIEF SCIENTIFIC OFFICER
  • 2021-04-14
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON US FDA GRANTING LICENSING PARTNER GILEAD SCIENCES, INC. ACCELERATED APPROVAL OF TRODELVY® FOR THE TREATMENT OF METASTATIC UROTHELIAL CANCER
  • 2021-04-12
    MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2021
  • 2021-04-09
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON LICENSING PARTNER GILEAD SCIENCES, INC. RECEIVING FULL US FDA APPROVAL OF TRODELVY® FOR THE TREATMENT OF PREVIOUSLY TREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER
  • 2021-03-31
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON CHINA NMPA APPROVAL OF CLINICAL TRIAL APPLICATION TO EVALUATE TRODELVY® IN A PHASE 2 BASKET TRIAL FOR A VARIETY OF CANCERS WITH HIGH TROP-2 EXPRESSION
  • 2021-03-22
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON ACCEPTANCE OF NEW DRUG APPLICATION BY CHINA NMPA FOR XERAVA FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN CHINA
  • 2021-03-10
    DATE OF BOARD MEETING
  • 2021-03-05
    MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2021
  • 2021-03-01
    VOLUNTARY ANNOUNCEMENT SELECTION AS A CONSTITUENT OF CERTAIN INDEXES OF HANG SENG INDEXES COMPANY LIMITED
  • 2021-02-18
    VOLUNTARY ANNOUNCEMENT APPOINTMENT OF CHIEF COMMERCIAL OFFICER

X

 Copyright Everest Medicines 2020   苏ICP备20038571号 |  Terms of Use |  Privacy Policy |  Disclaimers